

sex with a second 0.75 mg tablet taken 12 hours after the first tablet.

The background material will become available no later than the day before the meeting and will be posted under the Nonprescription Drugs Advisory Committee (NDAC) docket Web site at <http://www.fda.gov/ohrms/dockets/ac/acmenu.htm>. (Click on the year 2003 and scroll down to NDAC meetings.)

**Procedure:** Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions must be made to the contact person by December 5, 2003. Oral presentations from the public will be scheduled between approximately 11 a.m. and 12 noon. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before December 5, 2003, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Karen Templeton-Somers at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: November 17, 2003.

**Peter J. Pitts,**

*Associate Commissioner for External Relations.*

[FR Doc. 03-29334 Filed 11-24-03; 8:45 am]

BILLING CODE 4160-01-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Notice of Listing of Grants for Research Projects

**AGENCY:** National Institutes of Health, Department of Health and Human Services.

**ACTION:** Notice.

**SUMMARY:** Section 52.1(b) of the regulations governing grants for research projects, codified at 42 CFR part 52,

provides that the Secretary of Health and Human Services will periodically publish a list of all of the research project grant programs to which the research project grant regulations apply. This Notice provides the most recent list of the programs covered by the regulations and supersedes and replaces the prior Notice published October 24, 1996 (61 FR 55102-55106).

**EFFECTIVE DATE:** November 25, 2003.

**FOR FURTHER INFORMATION CONTACT:** Jerry Moore, NIH Regulations Officer, Office of Management Assessment, 6011 Executive Boulevard, Room 601, MSC 7669, Rockville, MD 20892, telephone (301) 496-4607 (not a toll-free number), fax (301) 402-0169, e-mail [jm40z@nih.gov](mailto:jm40z@nih.gov).

**SUPPLEMENTARY INFORMATION:** The National Institutes of Health (NIH) published a final rule in the **Federal Register** on October 24, 1996 (61 FR 55102-55106), amending the regulations at 42 CFR part 52, Grants for Research Projects, which govern Public Health Service (PHS) research project grants. The regulations were amended to apply to all research project grant programs administered by NIH and the Department of Health and Human Services (Department), except for grants for health services research, demonstration, and evaluation projects administered by the Agency for Health Care Policy and Research (AHCPR), to make it unnecessary to include a long list of programs in the regulations or to go through the lengthy process of amending the regulations each time a new program is established. At that time we provided in the preamble a listing of the applicable programs and indicated that we would periodically publish a list of the research project grant programs to which the regulations apply, and the applicability of the regulations to new programs would be announced as Department components initiated new programs.

We are publishing the list of programs to which the regulations apply to reflect the addition of new authorities in sections 317J, 317K, 317L, 330E, 399M, 399N, 409E, 434A, 445I, 447B, and 1261 of the Public Health Service Act (PHS Act), as amended. Section 317J of the PHS Act (42 U.S.C. 247b-11), as amended by section 601 of the Children's Health Act of 2000, Public Law 106-310, concerns research with respect to education and training for health professionals and the general public relating to the effects of folic acid in preventing birth defects. Section 317K of the PHS Act (42 U.S.C. 247b-12), as amended by section 901 of Public Law 106-310, concerns research

relating to risk factors, prevention strategies, and the roles of the family, health care providers, and the community in safe motherhood. Section 317L of the PHS Act (42 U.S.C. 247b-13), as amended by section 911 of Public Law 106-310, concerns epidemiological research on the prevention of prenatal and postnatal smoking, alcohol, and illegal drug use. Section 330E of the PHS Act (42 U.S.C. 254c-5), as amended by section 801 of Public Law 106-310, concerns research relating to intervention strategies to improve the lives of persons with epilepsy, particularly children. Section 399M of the PHS Act (42 U.S.C. 280g-1), as amended by section 702 of Public Law 106-310, concerns research relating to the efficacy of new screening techniques and technology, including clinical studies on the efficacy of new interventions, regarding hearing loss in infants. Section 399N of the PHS Act (42 U.S.C. 280g-2), as amended by section 1101 of Public Law 106-310, concerns research relating to improving the outcomes among children with childhood cancers and resultant secondary conditions. Section 409E of the PHS Act (42 U.S.C. 284i), as amended by section 1901 of Public Law 106-310, concerns research relating to autoimmune diseases. Section 434A of the PHS Act (42 U.S.C. 285c-9), as amended by section 402 of Public Law 106-310, concerns long-term epidemiology studies relating to type 1 or juvenile diabetes. Section 445I of the PHS Act (42 U.S.C. 285e-10a), as amended by section 801 of the Public Health Improvement Act, Public Law 106-505, concerns Alzheimer's Disease Clinical Research and Training Awards to enhance and promote the translation of new scientific knowledge into clinical practice related to the diagnosis, care, and treatment of individuals with Alzheimer's disease. Section 447B of the PHS Act (42 U.S.C. 285f-3), as amended by section 901 of the Public Health Improvement Act, Public Law 106-505, concerns Sexually Transmitted Disease Clinical Research and Training Awards to enhance and promote the translation of new scientific knowledge into clinical practice related to the diagnosis, care, and treatment of individuals with sexually transmitted diseases. Finally, section 1261 of the PHS Act (42 U.S.C. 300d-61), as amended by section 1303 of Public Law 106-310, concerns basic and applied research regarding traumatic brain injury, including the development, modification, and evaluation of therapies and programs of rehabilitation toward reaching or restoring normal capabilities.

The regulations codified at 42 CFR part 52 apply to all Public Health Service research project grant programs except for grants for health services research, demonstration, and evaluation projects administered by the AHCPR. Specifically, the research project grant authorities to which the Grants for Research Projects regulations apply include:

(1) Research into the cause, diagnosis, treatment, control, or prevention of the physical or mental diseases, injuries, or impairments to human life, as authorized by sections 301, 302, and related provisions of the PHS Act (42 U.S.C. 241, 242);

(2) Research into the prevention and control of childhood lead poisoning, as authorized under section 301 of the PHS Act (42 U.S.C. 241);

(3) Epidemiologic studies, and state-based research capacity building projects for the prevention of primary and secondary disabilities, as authorized under section 301 of the PHS Act (42 U.S.C. 241);

(4) Ecological and epidemiologic research studies in Lyme disease, including disease surveillance, development and evaluation of prevention and control studies, and development of improved diagnostic tests, as authorized under section 301 of the PHS Act (42 U.S.C. 241);

(5) Research for the development of knowledge and approaches to the epidemiology, etiology, diagnosis, treatment, control and prevention of narcotic addiction and intravenous (IV)-related AIDS and drug abuse, as authorized under sections 301 and 302 of the PHS Act (42 U.S.C. 241, 242);

(6) Investigations to identify strategies for prevention of childhood deaths from diarrhea, as authorized under sections 301 and 317(k) of the PHS Act (42 U.S.C. 241, 247b(k));

(7) HIV/AIDS surveillance, HIV serosurveillance surveys and studies, and epidemiologic research studies of AIDS and HIV infection, as authorized under sections 301 and 317(k) of the PHS Act (42 U.S.C. 241, 247b(k));

(8) Surveillance and epidemiologic studies for the prevention of infectious diseases and injuries in children in child day care settings, as authorized under sections 310, 317(k), and 391 of the PHS Act (42 U.S.C. 241, 247b(k), 280(b));

(9) Research into prevention and control of tuberculosis, especially research concerning strains of tuberculosis resistant to drugs and research concerning cases of tuberculosis that affect certain populations, as authorized by section

317E of the PHS Act (42 U.S.C. 247b-6);

(10) Research with respect to education and training for health professionals and the general public relating to the effects of folic acid in preventing birth defects, as authorized by section 317J of the PHS Act (42 U.S.C. 247b-11);

(11) Research relating to risk factors, prevention strategies, and the roles of the family, health care providers, and the community in safe motherhood, as authorized by section 317K of the PHS Act, as amended by section 901 of Public Law 106-310 (42 U.S.C. 424b-12);

(12) Epidemiological research on the prevention of prenatal and postnatal smoking, alcohol, and illegal drug use, as authorized by section 317L of the PHS Act, as amended by section 911 of Public Law 106-310 (42 U.S.C. 247b-13);

(13) Research relating to intervention strategies to improve the lives of persons with epilepsy, particularly children, as authorized by section 330E of the PHS Act (42 U.S.C. 254c-5);

(14) Injury prevention and control research, as authorized by section 391 of the PHS Act (42 U.S.C. 280b);

(15) Research relating to the efficacy of new screening techniques and technology, including clinical studies of screening methods and studies on the efficacy of new interventions, regarding hearing loss in infants, as authorized by section 399M of the PHS Act, as amended by section 702 of Public Law 106-310 (42 U.S.C. 280g-1);

(16) Research relating to improving the outcomes among children with childhood cancers and resultant secondary conditions, as authorized by section 399N of the PHS Act, as amended by section 1101 of Public Law 106-310 (42 U.S.C. 280g-2);

(17) Research on osteoporosis, Paget's disease and related bone disorders, as authorized by section 409A of the PHS Act (42 U.S.C. 284e);

(18) Research relating to autoimmune diseases, as authorized by section 409E of the PHS Act, as amended by section 1901 of Public Law 106-310 (42 U.S.C. 284i);

(19) Long-term epidemiology studies relating to type 1 or juvenile diabetes, as authorized by section 434A of the PHS Act, as amended by section 402 of Public Law 106-310 (42 U.S.C. 285c-9);

(20) Biomedical research in areas relating to Alzheimer's disease and related dementias, as authorized by section 445B of the PHS Act (42 U.S.C. 285e-4);

(21) Clinical research and training to enhance and promote the translation of new scientific knowledge into clinical

practice related to the diagnosis, care and treatment of individuals with Alzheimer's disease, as authorized by section 445I of the PHS Act (42 U.S.C. 285e-10a);

(22) Clinical research and training to enhance and promote the translation of new scientific knowledge into clinical practice related to the diagnosis, care, and treatment of individuals with sexually transmitted diseases, as authorized by section 447B of the PHS Act, as amended by section 901 of Public Law 106-505 (42 U.S.C. 285f-3);

(23) Research relating to medical rehabilitation, as authorized by section 452 of the PHS Act (42 U.S.C. 285g-4);

(24) Research on clinical and health services on eye care and diabetes, as authorized by section 456 of the PHS Act (42 U.S.C. 285i-1);

(25) Research on multiple sclerosis, especially research on the effects of genetics and hormonal changes on the progress of the disease, as authorized by section 460 of the PHS Act (42 U.S.C. 285j-3);

(26) Research on the social, behavioral, and biomedical etiology, mental and physical health consequences, and social and economic consequences of alcohol abuse and alcoholism, as authorized by 464H of the PHS Act (42 U.S.C. 285n);

(27) Health services research activities with respect to the prevention of alcohol abuse and treatment of alcoholism, as authorized by section 464H of the PHS Act (42 U.S.C. 285n) and defined in section 409 of the PHS Act (42 U.S.C. 284d);

(28) Research under the Medication Development Program to encourage and promote the development and use medications to treat drug addiction; and to collect, analyze, and disseminate data, as authorized by section 464P of the PHS Act (42 U.S.C. 285o-4);

(29) Research on health related educational technologies, medical library science and related activities, and for the development or dissemination of new knowledge, techniques, systems, and equipment for processing, storing, retrieving, and distributing information pertaining to health sciences, as authorized by section 473 of the PHS Act (42 U.S.C. 286b-4);

(30) Research in the biomedical, contraceptive, development, behavioral and program implementation fields related to family planning and population, as authorized by section 1004 of the PHS Act (42 U.S.C. 300a-2);

(31) Basic and applied research regarding traumatic brain injury, including the development, modification, and evaluation of

therapies and programs of rehabilitation toward reaching or restoring normal capabilities, as authorized by section 1261 of the PHS Act, as amended by section 1301 of Public Law 106-310 (42 U.S.C. 300d-61);

(32) Research on the causes, consequences and approaches of coping with adolescent sexual relations, contraceptive use, pregnancy, and parenthood, as authorized by section 2008 of the PHS Act (42 U.S.C. 300z-7);

(33) Research relating to the evaluation of drug treatments for AIDS not approved by the Commissioner of Food and Drugs, as authorized by section 2314 of the PHS Act (42 U.S.C. 300cc-14);

(34) International research relating to the development and evaluation of vaccines and treatments for AIDS, as authorized by section 2315 of the PHS Act (42 U.S.C. 300cc-15);

(35) Long-term research into treatments for AIDS, as authorized by section 2320 of the PHS Act (42 U.S.C. 300cc-20);

(36) Research relating to AIDS conducted outside of the United States by qualified foreign professionals and collaborative research involving American and foreign participants, as authorized by section 2354 of the PHS Act (42 U.S.C. 300cc-41);

(37) Basic research to identify, characterize, and quantify risks to human health from air pollutants, as authorized by section 103 of the Clean Air Act, as amended (42 U.S.C. 7403);

(38) Electronic product radiation control research programs designed to protect the public health and safety from electronic product radiation, as authorized by section 532 of the Federal Food, Drug, and Cosmetic Act, as amended (21 U.S.C. 360ii);

(39) Research into areas where a microgravity environment may contribute to significant progress in the understanding and treatment of diseases and other medical conditions, as authorized by section 603 of the National Aeronautics and Space Administration Authorization Act, Fiscal Year 1993 (42 U.S.C. 2487b);

(40) Support for radiation studies and research, as authorized under section 301 of the PHS Act (42 U.S.C. 241) and by section 20(a) of the Occupational Safety and Health Act of 1970 (29 U.S.C. 669(a));

(41) Research on occupational safety and health problems in industry, as authorized by section 20(a) of the Occupational Safety and Health Act of 1970 (29 U.S.C. 669(a)) and section 501 of the Federal Coal Mine Health and Safety Act of 1969 (30 U.S.C. 951); and

(42) Research to stimulate health-related technological innovation, especially through the use of small business, minority, and disadvantaged firms and increased private sector commercialization of innovations derived from federal research and development, as authorized under section 301 of the PHS Act (42 U.S.C. 241), in accordance with the procedures prescribed pursuant to section 2 [9] of the Small Business Innovation Development Act of 1982, as amended (15 U.S.C. 638).

The Catalogue of Federal Domestic Assistance (CFDA) numbered programs affected by title 42 of the Code of Federal Regulations, part 52, are:

93.113—Biological Response to Environmental Health Hazards  
 93.114—Applied Toxicological Research and Testing  
 93.115—Biometry and Risk Estimation” Health Risks from Environmental Exposures  
 93.118—Acquired Immunodeficiency Syndrome (AIDS) Activity  
 93.121—Oral Diseases and Disorders Research  
 93.135—Centers for Research and Demonstration for Health Promotion and Disease Prevention  
 93.136—Injury Control Research Projects  
 93.154—Special International Postdoctoral Research Program in Acquired Immunodeficiency Syndrome (AIDS)  
 93.172—Human Genome Research  
 93.173—Biological Research Related to Deafness and Communicative Disorders  
 93.184—Disabilities Prevention  
 93.198—Biological Models and Materials Resources Program  
 93.242—Mental Health Research Grants  
 93.262—Occupational Safety and Health Research Grants  
 93.271—Alcohol Scientist Development Award; Scientist Development Award for Clinicians; and Research Scientist Award  
 93.172—Human Genome Research  
 93.273—Alcohol Research Programs  
 93.277—Drug Abuse Scientist Development Award for Clinicians, and Scientist Development Awards  
 93.279—Drug Abuse Research Programs  
 93.281—Mental Health Research Scientist Development Award, Research Scientist Development Award for Clinicians, and Research Scientist Award  
 93.283—Centers for Disease Control—Investigation and Technical Assistance  
 93.306—Comparative Medicine Program (formerly called Laboratory Animal Sciences and Primate Research)

93.333—General Clinical Research Centers  
 93.361—Nursing Research  
 93.371—Biomedical Research Technology  
 93.389—Research Centers in Minority Institutions  
 93.390—Academic Research Enhancement Award  
 93.393—Cancer Cause and Prevention Research  
 93.394—Cancer Detection and Diagnosis Research  
 93.395—Cancer Treatment Research  
 93.396—Cancer Biology Research  
 93.821—Biophysics and Physiological Sciences Research  
 93.837—Heart and Vascular Diseases Research  
 93.838—Lung Diseases Research 13  
 93.839—Blood Diseases and Resources Research  
 93.846—Arthritis, Musculoskeletal and Skin Diseases Research  
 93.847—Diabetes, Endocrinology and Metabolic Research  
 93.848—Digestive Diseases and Nutrition Research  
 93.849—Kidney Diseases, Urology and Hematology Research  
 93.853—Clinical Research Related to Neurological Disorders  
 93.854—Biological Basic Research in the Neurosciences  
 93.855—Allergy, Immunology, and Transplantation Research  
 93.856—Microbiology and Infectious Diseases Research  
 93.859—Pharmacological Sciences  
 93.862—Genetics Research  
 93.863—Cellular and Molecular Basis of Disease Research  
 93.864—Population Research  
 93.865—Research for Mothers and Children  
 93.866—Aging Research  
 93.867—Vision Research  
 93.879—Medical Library Assistance  
 93.929—Center for Medical Rehabilitation Research  
 93.934—Fogarty International Research Collaboration Award  
 93.939—Blood Diseases and Resources Research  
 93.941—HIV Demonstration, Research, Public and Professional Education Projects  
 93.942—Research, Treatment and Education Programs on Lyme Disease in the United States  
 93.943—Epidemiologic Research Studies of Acquired Immunodeficiency Syndrome (AIDS) and Human Immunodeficiency Virus (HIV) Infection in Selected Population Groups  
 93.947—Tuberculosis Demonstration, Research, Public and Professional Education

Dated: September 29, 2003.  
**Elias A. Zerhouni**,  
 Director, National Institutes of Health.  
 Approved: November 10, 2003.  
**Tommy G. Thompson**,  
 Secretary.  
 [FR Doc. 03-29410 Filed 11-25-03; 8:45 am]  
**BILLING CODE 4140-01-P**

**DEPARTMENT OF HOMELAND SECURITY**

**Federal Emergency Management Agency**

**Agency Information Collection Activities: Proposed Collection; Comment Request**

**AGENCY:** Federal Emergency Management Agency, Emergency Preparedness and Response Directorate, U.S. Department of Homeland Security.

**ACTION:** Notice and request for comments.

**SUMMARY:** The Federal Emergency Management Agency, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed new information collections. In accordance with the Paperwork Reduction Act of 1995 (44 U.S.C. 3506(c)(2)(A)), this notice seeks comments concerning customer

satisfaction with Building Science & Technology publications that contain guidance on construction practices in reducing damage from natural and man-made hazards.

**SUPPLEMENTARY INFORMATION:** Executive Order 12862 requires Federal agencies to survey their customers in order to determine the kind and quality of services they want and their level of satisfaction with existing services. FEMA wishes to obtain feedback from users of Buildings Science and Technology (BS&T) publications, particularly from those who have ordered publications in the past three years. The publications offer state-of-the-art construction practices for building safety and to reduce the risk of future damage from natural and man-made hazards. The feedback project is an opportunity for customers to evaluate publications as a whole, with a special focus on construction in flood hazard areas, including coastal area. With customer feedback information, BS&T can revise and otherwise improve the presentation of technical information to better suit the needs and desires of customers, thereby improving building safety and successfully reducing future building losses from natural and man-made hazards.

**Collection of Information**

*Title:* Building Science & Technology (BS&T) Publications Customer Satisfaction Research, FEMA.

*Type of Information:* New.

*Abstract:* (1) 2004 On-Line Survey: Since BS&T's mission is to improve the safety of the built environment, the feedback project evaluates customer satisfaction with building science publications, as well as customer reports on how the publications are used, their impact on building safety, and how they could be improved. (2) 2004 Focus Groups (4): With completion of the on-line survey, subject matter experts who use the publications will be recruited to participate in regional focus groups to solicit feedback on the format and content of BS&T publications. (3) 2005-6 Ongoing Customer Feedback: BS&T will use the findings of the benchmark survey not only to make needed changes immediately but to establish a base-line of information for judging whether customer satisfaction is changing over time. With each publication ordered, a self-mailer postcard will be included that encourages the customer to provide feedback on the usefulness of specific publications and any comments.

*Affected Public:* The people and organizations affected by this survey include: (a) Individuals or households, (b) business or other for-profit, (c) not-for-profit institutions (d) Federal government, and (e) State, local or tribal government.

*Estimated Total Annual Burden Hours:* 496 hours.

FEMA forms	Number of respondents (A)	Frequency of response (B)	Hours per response (C)	Annual burden hours (A x B x C)
2004 On-Line Survey .....	1,000	1	0.17	200
Focus Groups (4) .....	48	1	6.0	288
2005-2006 On-Going Customer Feedback .....	390	1	0.02	8
<b>Total .....</b>	<b>1438</b>	<b>1</b>	<b>0.02</b>	<b>496</b>

*Estimated Cost:* \$10,396.00.

Program	Burden hours	Median hourly rate \$	Average cost/respondent hour \$	Annualized cost all respondents
On-Line Survey/Pre-Survey .....	200	20.96	3.56	\$4,192.00
Focus Groups .....	288	20.96	3.56	6,036.00
On-Going Customer Feedback .....	8	20.96	3.56	168.00
<b>Grand total .....</b>	<b>496</b>	<b>.....</b>	<b>.....</b>	<b>10,396.00</b>

*Comments:* Written comments are solicited to: (a) Evaluate whether the proposed data collection is necessary for the proper performance of the agency, including whether the information shall have practical utility; (b) evaluate the accuracy of the agency's estimate of the

burden of the proposed collection of information, including the validity of the methodology and assumptions used; (c) enhance the quality, utility, and clarity of the information to be collected; and (d) minimize the burden of the collection of information on those

who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. Comments should be